 Richard Vandivier
Concepts (419)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 20 | 2022 | 902 | 3.360 |
Why?
| | Apoptosis | 22 | 2014 | 2288 | 2.170 |
Why?
| | Phagocytosis | 14 | 2014 | 335 | 2.050 |
Why?
| | Macrophages, Alveolar | 13 | 2019 | 341 | 1.210 |
Why?
| | Tobacco Smoke Pollution | 3 | 2022 | 218 | 1.180 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 204 | 1.090 |
Why?
| | Pulmonary Embolism | 2 | 2018 | 181 | 1.060 |
Why?
| | Respiratory Insufficiency | 3 | 2022 | 285 | 0.900 |
Why?
| | Smoking | 5 | 2018 | 1380 | 0.770 |
Why?
| | Adrenal Cortex Hormones | 2 | 2015 | 488 | 0.730 |
Why?
| | Lung | 11 | 2022 | 3497 | 0.690 |
Why?
| | rhoA GTP-Binding Protein | 6 | 2014 | 72 | 0.680 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 238 | 0.670 |
Why?
| | Pneumonia | 6 | 2023 | 561 | 0.600 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 66 | 0.600 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2011 | 229 | 0.570 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 230 | 0.520 |
Why?
| | Cigarette Smoking | 1 | 2017 | 73 | 0.520 |
Why?
| | Critical Illness | 8 | 2020 | 653 | 0.470 |
Why?
| | Stem Cells | 2 | 2018 | 538 | 0.470 |
Why?
| | rac1 GTP-Binding Protein | 3 | 2012 | 53 | 0.470 |
Why?
| | Pulmonary Alveoli | 4 | 2016 | 369 | 0.470 |
Why?
| | Methylprednisolone | 1 | 2014 | 80 | 0.440 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 71 | 0.430 |
Why?
| | Bronchiectasis | 2 | 2006 | 105 | 0.420 |
Why?
| | Alcoholism | 5 | 2023 | 704 | 0.420 |
Why?
| | Asthma | 3 | 2022 | 2016 | 0.420 |
Why?
| | Humans | 61 | 2023 | 113531 | 0.400 |
Why?
| | Coronary Disease | 1 | 2015 | 347 | 0.400 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 496 | 0.400 |
Why?
| | Case Management | 1 | 2012 | 61 | 0.400 |
Why?
| | rho GTP-Binding Proteins | 2 | 2010 | 59 | 0.390 |
Why?
| | Hospital Mortality | 5 | 2020 | 780 | 0.390 |
Why?
| | Serotonin | 1 | 2014 | 284 | 0.390 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 67 | 0.380 |
Why?
| | Cystic Fibrosis | 4 | 2006 | 953 | 0.380 |
Why?
| | Patient Education as Topic | 2 | 2012 | 665 | 0.350 |
Why?
| | Mice | 20 | 2017 | 14679 | 0.330 |
Why?
| | Inflammation Mediators | 4 | 2016 | 469 | 0.320 |
Why?
| | Hospitalization | 5 | 2023 | 1765 | 0.310 |
Why?
| | Signal Transduction | 6 | 2014 | 4439 | 0.300 |
Why?
| | Male | 33 | 2022 | 55112 | 0.300 |
Why?
| | Interleukin-8 | 1 | 2009 | 230 | 0.300 |
Why?
| | Neutrophils | 6 | 2010 | 1072 | 0.300 |
Why?
| | Animals | 29 | 2017 | 31162 | 0.300 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2018 | 1822 | 0.290 |
Why?
| | Female | 31 | 2022 | 59115 | 0.290 |
Why?
| | Quality of Life | 3 | 2022 | 2335 | 0.290 |
Why?
| | Intensive Care Units | 5 | 2019 | 620 | 0.280 |
Why?
| | Inflammation | 8 | 2016 | 2444 | 0.280 |
Why?
| | Acyl Coenzyme A | 1 | 2006 | 29 | 0.270 |
Why?
| | Intracellular Fluid | 1 | 2006 | 27 | 0.270 |
Why?
| | rho-Associated Kinases | 3 | 2014 | 80 | 0.270 |
Why?
| | Lovastatin | 1 | 2006 | 26 | 0.260 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2009 | 287 | 0.260 |
Why?
| | Lung Diseases, Obstructive | 1 | 2006 | 41 | 0.260 |
Why?
| | Middle Aged | 19 | 2022 | 26552 | 0.260 |
Why?
| | Ethanol | 1 | 2010 | 532 | 0.260 |
Why?
| | Self Care | 1 | 2009 | 350 | 0.260 |
Why?
| | Collectins | 1 | 2006 | 10 | 0.260 |
Why?
| | Opsonin Proteins | 1 | 2006 | 24 | 0.260 |
Why?
| | Cells, Cultured | 8 | 2016 | 3802 | 0.260 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2006 | 127 | 0.250 |
Why?
| | Jurkat Cells | 5 | 2012 | 122 | 0.250 |
Why?
| | Leukocyte Elastase | 2 | 2002 | 70 | 0.240 |
Why?
| | Cohort Studies | 6 | 2022 | 4880 | 0.240 |
Why?
| | Disease Progression | 4 | 2020 | 2364 | 0.230 |
Why?
| | Mice, Inbred C57BL | 10 | 2014 | 4617 | 0.230 |
Why?
| | Shock, Septic | 2 | 2022 | 185 | 0.230 |
Why?
| | Oligopeptides | 1 | 2006 | 231 | 0.230 |
Why?
| | Mice, Knockout | 7 | 2014 | 2523 | 0.220 |
Why?
| | Retrospective Studies | 10 | 2023 | 12504 | 0.220 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 4 | 2016 | 28 | 0.220 |
Why?
| | Erythropoietin | 1 | 2004 | 69 | 0.220 |
Why?
| | Lipopolysaccharides | 5 | 2016 | 802 | 0.220 |
Why?
| | Respiratory System | 2 | 2018 | 137 | 0.210 |
Why?
| | Extracellular Matrix | 1 | 2006 | 433 | 0.200 |
Why?
| | Treatment Outcome | 5 | 2022 | 9006 | 0.200 |
Why?
| | Patient Discharge | 2 | 2018 | 770 | 0.190 |
Why?
| | Macrophages | 5 | 2010 | 1233 | 0.190 |
Why?
| | Aged | 13 | 2022 | 18944 | 0.190 |
Why?
| | Transforming Growth Factor beta | 4 | 2013 | 435 | 0.180 |
Why?
| | Smoke-Free Policy | 1 | 2021 | 13 | 0.180 |
Why?
| | Autoimmune Diseases | 2 | 2014 | 379 | 0.180 |
Why?
| | Smokers | 2 | 2019 | 129 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2009 | 1106 | 0.170 |
Why?
| | Ibuprofen | 3 | 1999 | 75 | 0.170 |
Why?
| | Adult | 17 | 2021 | 30245 | 0.170 |
Why?
| | Noninvasive Ventilation | 1 | 2020 | 31 | 0.170 |
Why?
| | Mice, Inbred ICR | 3 | 2013 | 108 | 0.170 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 347 | 0.170 |
Why?
| | Granulomatous Disease, Chronic | 2 | 2010 | 51 | 0.160 |
Why?
| | Nitroprusside | 1 | 1999 | 64 | 0.160 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.160 |
Why?
| | Hexosaminidases | 1 | 2019 | 17 | 0.160 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 27 | 0.160 |
Why?
| | Macrolides | 1 | 2019 | 56 | 0.150 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 216 | 0.150 |
Why?
| | Pharmacoepidemiology | 2 | 2019 | 20 | 0.150 |
Why?
| | Aged, 80 and over | 7 | 2022 | 6296 | 0.150 |
Why?
| | Bronchoalveolar Lavage Fluid | 5 | 2016 | 578 | 0.150 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 6 | 0.150 |
Why?
| | Atracurium | 1 | 2018 | 13 | 0.150 |
Why?
| | Disease Models, Animal | 5 | 2017 | 3470 | 0.150 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 21 | 0.150 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 21 | 0.150 |
Why?
| | Coronary Circulation | 1 | 2018 | 131 | 0.150 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 23 | 0.150 |
Why?
| | Time | 1 | 2018 | 70 | 0.150 |
Why?
| | Cardiologists | 1 | 2018 | 40 | 0.150 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1465 | 0.150 |
Why?
| | Counseling | 1 | 2021 | 342 | 0.150 |
Why?
| | Occupational Therapy | 1 | 2019 | 74 | 0.150 |
Why?
| | Critical Care | 2 | 2020 | 474 | 0.150 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 138 | 0.140 |
Why?
| | Hypertension, Pulmonary | 4 | 2016 | 1733 | 0.140 |
Why?
| | Polyneuropathies | 1 | 2017 | 50 | 0.140 |
Why?
| | Environmental Exposure | 1 | 2021 | 370 | 0.140 |
Why?
| | Up-Regulation | 2 | 2019 | 794 | 0.140 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 2 | 2008 | 24 | 0.140 |
Why?
| | Epithelium | 1 | 2018 | 293 | 0.140 |
Why?
| | Length of Stay | 3 | 2019 | 963 | 0.140 |
Why?
| | Propensity Score | 2 | 2017 | 225 | 0.140 |
Why?
| | Disease-Free Survival | 1 | 2018 | 617 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 166 | 0.140 |
Why?
| | Nitric Oxide | 3 | 2006 | 814 | 0.140 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 469 | 0.140 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1236 | 0.130 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 265 | 0.130 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 412 | 0.130 |
Why?
| | DNA, Bacterial | 1 | 2017 | 308 | 0.130 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 139 | 0.130 |
Why?
| | Receptors, IgG | 2 | 2009 | 66 | 0.130 |
Why?
| | Respiratory Mucosa | 2 | 2009 | 251 | 0.130 |
Why?
| | Endotoxins | 4 | 2013 | 211 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 231 | 0.120 |
Why?
| | Emphysema | 3 | 2012 | 105 | 0.120 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2293 | 0.120 |
Why?
| | Biopsy | 1 | 2018 | 1024 | 0.120 |
Why?
| | Anticoagulants | 1 | 2018 | 548 | 0.120 |
Why?
| | CD36 Antigens | 2 | 2006 | 34 | 0.110 |
Why?
| | Hyaluronan Receptors | 2 | 2006 | 90 | 0.110 |
Why?
| | Schistosomiasis mansoni | 1 | 2013 | 19 | 0.110 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 60 | 0.110 |
Why?
| | Schistosoma mansoni | 1 | 2013 | 33 | 0.110 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 679 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 487 | 0.110 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2016 | 216 | 0.110 |
Why?
| | Echocardiography | 1 | 2016 | 563 | 0.110 |
Why?
| | Interleukin-6 | 3 | 2013 | 661 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 310 | 0.100 |
Why?
| | Biological Transport | 1 | 2014 | 363 | 0.100 |
Why?
| | Thymus Gland | 1 | 2014 | 291 | 0.100 |
Why?
| | Mice, Transgenic | 3 | 2013 | 1925 | 0.100 |
Why?
| | Acute Disease | 1 | 2015 | 885 | 0.100 |
Why?
| | Cell Line | 4 | 2012 | 2581 | 0.100 |
Why?
| | Adolescent | 5 | 2022 | 17724 | 0.100 |
Why?
| | Doxycycline | 1 | 2012 | 53 | 0.100 |
Why?
| | Phosphatidylserines | 2 | 2008 | 80 | 0.090 |
Why?
| | Colitis | 1 | 2014 | 220 | 0.090 |
Why?
| | Acetylcysteine | 2 | 2016 | 141 | 0.090 |
Why?
| | Rural Health Services | 1 | 2011 | 92 | 0.090 |
Why?
| | Pyrroles | 1 | 2012 | 179 | 0.090 |
Why?
| | Membrane Glycoproteins | 3 | 2010 | 420 | 0.090 |
Why?
| | Bronchoalveolar Lavage | 3 | 2017 | 82 | 0.090 |
Why?
| | Glucocorticoids | 1 | 2015 | 520 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 442 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2530 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1421 | 0.090 |
Why?
| | Microbiota | 1 | 2017 | 646 | 0.090 |
Why?
| | In Vitro Techniques | 2 | 2002 | 996 | 0.090 |
Why?
| | Ceramides | 1 | 2010 | 91 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2013 | 266 | 0.080 |
Why?
| | Peritonitis | 1 | 2010 | 75 | 0.080 |
Why?
| | Phosphorylation | 1 | 2014 | 1537 | 0.080 |
Why?
| | Amides | 1 | 2010 | 87 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2011 | 541 | 0.080 |
Why?
| | Indoles | 1 | 2012 | 296 | 0.080 |
Why?
| | Stress Fibers | 1 | 2009 | 16 | 0.080 |
Why?
| | Amiloride | 1 | 2009 | 23 | 0.080 |
Why?
| | Thiazolidinediones | 1 | 2010 | 134 | 0.080 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 2 | 2006 | 14 | 0.080 |
Why?
| | Alcohol-Related Disorders | 1 | 2010 | 112 | 0.080 |
Why?
| | Oxygen Consumption | 1 | 2011 | 568 | 0.080 |
Why?
| | PPAR gamma | 1 | 2010 | 179 | 0.080 |
Why?
| | Risk Factors | 4 | 2018 | 8606 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 712 | 0.080 |
Why?
| | Antigens, Differentiation | 1 | 2008 | 77 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2009 | 384 | 0.070 |
Why?
| | Telephone | 1 | 2009 | 152 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 4400 | 0.070 |
Why?
| | Interleukin-4 | 1 | 2008 | 202 | 0.070 |
Why?
| | Gene Expression | 2 | 2010 | 1397 | 0.070 |
Why?
| | Epithelial Cells | 2 | 2010 | 939 | 0.070 |
Why?
| | Actins | 1 | 2009 | 373 | 0.070 |
Why?
| | Models, Biological | 1 | 2014 | 1589 | 0.070 |
Why?
| | Receptors, Immunologic | 1 | 2008 | 195 | 0.070 |
Why?
| | Heart Rate | 3 | 2005 | 705 | 0.070 |
Why?
| | Pyridines | 1 | 2010 | 417 | 0.070 |
Why?
| | Blotting, Western | 1 | 2009 | 1128 | 0.070 |
Why?
| | Hydroxymethylglutaryl CoA Reductases | 1 | 2006 | 10 | 0.070 |
Why?
| | Free Radical Scavengers | 1 | 2006 | 78 | 0.070 |
Why?
| | Protein Prenylation | 1 | 2006 | 19 | 0.070 |
Why?
| | Protein Biosynthesis | 1 | 2008 | 375 | 0.070 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1282 | 0.070 |
Why?
| | Mannose-Binding Lectin | 1 | 2006 | 19 | 0.060 |
Why?
| | Lysophospholipids | 1 | 2006 | 60 | 0.060 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 155 | 0.060 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2006 | 122 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2006 | 95 | 0.060 |
Why?
| | Respiration, Artificial | 2 | 2020 | 536 | 0.060 |
Why?
| | Health Care Costs | 1 | 2009 | 381 | 0.060 |
Why?
| | Antigens, CD | 2 | 2006 | 437 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2006 | 111 | 0.060 |
Why?
| | Arginine | 1 | 2006 | 235 | 0.060 |
Why?
| | Bronchi | 1 | 2006 | 222 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2361 | 0.060 |
Why?
| | omega-N-Methylarginine | 1 | 2005 | 26 | 0.060 |
Why?
| | Neoplasms | 1 | 2018 | 2082 | 0.060 |
Why?
| | Regeneration | 1 | 2006 | 158 | 0.060 |
Why?
| | Patient Satisfaction | 1 | 2009 | 570 | 0.060 |
Why?
| | HIV Infections | 1 | 2019 | 2440 | 0.060 |
Why?
| | MAP Kinase Signaling System | 1 | 2006 | 267 | 0.060 |
Why?
| | Erythrocytes | 1 | 2009 | 566 | 0.060 |
Why?
| | Databases, Factual | 2 | 2019 | 1127 | 0.060 |
Why?
| | Blood Pressure | 3 | 2016 | 1521 | 0.060 |
Why?
| | Sepsis | 2 | 2020 | 505 | 0.060 |
Why?
| | Fibroblasts | 1 | 2008 | 827 | 0.060 |
Why?
| | Collagen | 1 | 2006 | 411 | 0.050 |
Why?
| | Nitrates | 2 | 2005 | 70 | 0.050 |
Why?
| | Lung Diseases | 2 | 2009 | 688 | 0.050 |
Why?
| | Membrane Proteins | 2 | 2006 | 1008 | 0.050 |
Why?
| | Monocytes | 1 | 2006 | 499 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 1872 | 0.050 |
Why?
| | Patient Readmission | 2 | 2019 | 608 | 0.050 |
Why?
| | Complement Activation | 1 | 2006 | 332 | 0.050 |
Why?
| | Oxidative Stress | 1 | 2009 | 1065 | 0.050 |
Why?
| | Immunotherapy | 1 | 2006 | 472 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 2690 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 371 | 0.050 |
Why?
| | Pulmonary Surfactant-Associated Proteins | 1 | 2002 | 10 | 0.050 |
Why?
| | Colorado | 1 | 2011 | 4061 | 0.050 |
Why?
| | Cathepsin G | 1 | 2002 | 6 | 0.050 |
Why?
| | Proteolipids | 1 | 2002 | 28 | 0.050 |
Why?
| | Cathepsins | 1 | 2002 | 22 | 0.050 |
Why?
| | Young Adult | 4 | 2019 | 10400 | 0.050 |
Why?
| | Vasopressins | 1 | 2022 | 56 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2008 | 1681 | 0.050 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 192 | 0.050 |
Why?
| | Heart Diseases | 1 | 2005 | 327 | 0.050 |
Why?
| | Serine Endopeptidases | 1 | 2002 | 101 | 0.050 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 113 | 0.050 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2002 | 57 | 0.050 |
Why?
| | Single-Blind Method | 2 | 1999 | 255 | 0.050 |
Why?
| | Pulmonary Surfactants | 1 | 2002 | 100 | 0.050 |
Why?
| | Norepinephrine | 1 | 2022 | 197 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2004 | 1214 | 0.050 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 12 | 0.050 |
Why?
| | Status Asthmaticus | 1 | 2020 | 10 | 0.050 |
Why?
| | United States | 4 | 2019 | 12137 | 0.040 |
Why?
| | Chronic Disease | 1 | 2006 | 1570 | 0.040 |
Why?
| | Cross-Over Studies | 2 | 1999 | 432 | 0.040 |
Why?
| | Glycoproteins | 1 | 2002 | 302 | 0.040 |
Why?
| | Vascular Resistance | 2 | 2016 | 337 | 0.040 |
Why?
| | Sputum | 1 | 2002 | 284 | 0.040 |
Why?
| | Autoimmunity | 1 | 2006 | 813 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 2993 | 0.040 |
Why?
| | NADPH Oxidase 2 | 2 | 2010 | 37 | 0.040 |
Why?
| | NADPH Oxidases | 2 | 2010 | 96 | 0.040 |
Why?
| | Cyclic GMP | 1 | 1999 | 78 | 0.040 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 1999 | 12 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2004 | 1205 | 0.040 |
Why?
| | Fever | 2 | 1999 | 266 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1136 | 0.040 |
Why?
| | Endothelium, Vascular | 2 | 2003 | 829 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 1999 | 368 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2018 | 31 | 0.040 |
Why?
| | Time Factors | 2 | 2018 | 6032 | 0.040 |
Why?
| | Endotoxemia | 1 | 1999 | 86 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 131 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 1999 | 205 | 0.040 |
Why?
| | Hospital Charges | 1 | 2017 | 39 | 0.040 |
Why?
| | Hospitals, Urban | 1 | 2018 | 128 | 0.040 |
Why?
| | Cellular Reprogramming | 1 | 2018 | 85 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2019 | 325 | 0.040 |
Why?
| | Biomarkers | 2 | 2019 | 3389 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 4593 | 0.040 |
Why?
| | Muscular Diseases | 1 | 2017 | 101 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2018 | 175 | 0.030 |
Why?
| | Lung Diseases, Interstitial | 1 | 2002 | 494 | 0.030 |
Why?
| | Acute Kidney Injury | 2 | 2014 | 676 | 0.030 |
Why?
| | Cytokines | 3 | 2013 | 1795 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1443 | 0.030 |
Why?
| | Teichoic Acids | 1 | 2016 | 12 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 223 | 0.030 |
Why?
| | Systole | 1 | 2016 | 173 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1497 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 134 | 0.030 |
Why?
| | Risk | 1 | 2018 | 807 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 479 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 2 | 2009 | 33 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2016 | 110 | 0.030 |
Why?
| | Cell Membrane | 2 | 2010 | 663 | 0.030 |
Why?
| | Dogs | 2 | 2006 | 325 | 0.030 |
Why?
| | Amino Acid Oxidoreductases | 1 | 1994 | 18 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 716 | 0.030 |
Why?
| | Hemorrhage | 1 | 2018 | 599 | 0.030 |
Why?
| | Immunologic Factors | 1 | 1996 | 211 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 442 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 633 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2009 | 1065 | 0.030 |
Why?
| | Ipilimumab | 1 | 2014 | 27 | 0.030 |
Why?
| | Phylogeny | 1 | 2017 | 783 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 599 | 0.030 |
Why?
| | Infliximab | 1 | 2014 | 93 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2013 | 77 | 0.030 |
Why?
| | Endothelial Cells | 2 | 2010 | 677 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2013 | 51 | 0.030 |
Why?
| | Toll-Like Receptor 4 | 1 | 2016 | 285 | 0.030 |
Why?
| | Diarrhea | 1 | 2014 | 170 | 0.030 |
Why?
| | Logistic Models | 1 | 2017 | 1832 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2018 | 479 | 0.030 |
Why?
| | Hypotension | 1 | 2014 | 115 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2139 | 0.030 |
Why?
| | Transfection | 2 | 2006 | 842 | 0.030 |
Why?
| | Vasoconstriction | 1 | 2013 | 174 | 0.020 |
Why?
| | Antioxidants | 1 | 2016 | 527 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 540 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 1999 | 2752 | 0.020 |
Why?
| | Trachea | 1 | 2013 | 220 | 0.020 |
Why?
| | Pulmonary Circulation | 1 | 2013 | 400 | 0.020 |
Why?
| | Creatinine | 1 | 2013 | 434 | 0.020 |
Why?
| | Ceramidases | 1 | 2010 | 4 | 0.020 |
Why?
| | Zymosan | 1 | 2010 | 62 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2013 | 1208 | 0.020 |
Why?
| | Nitric Oxide Synthase | 2 | 2005 | 209 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2010 | 2507 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 46 | 0.020 |
Why?
| | Rats | 2 | 2010 | 4829 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 68 | 0.020 |
Why?
| | Capillaries | 1 | 2009 | 90 | 0.020 |
Why?
| | Gene Deletion | 1 | 2010 | 351 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 914 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2008 | 133 | 0.020 |
Why?
| | Leukocytes | 1 | 2009 | 268 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2008 | 192 | 0.020 |
Why?
| | Melanoma | 1 | 2014 | 620 | 0.020 |
Why?
| | Pulmonary Emphysema | 1 | 2010 | 265 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2009 | 288 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 783 | 0.020 |
Why?
| | ATP Binding Cassette Transporter 1 | 1 | 2006 | 10 | 0.020 |
Why?
| | Receptors, LDL | 1 | 2006 | 38 | 0.020 |
Why?
| | Complement C1q | 1 | 2006 | 36 | 0.020 |
Why?
| | Gene Targeting | 1 | 2006 | 75 | 0.020 |
Why?
| | Syk Kinase | 1 | 2006 | 18 | 0.020 |
Why?
| | Fetal Distress | 1 | 2006 | 12 | 0.020 |
Why?
| | Random Allocation | 1 | 2006 | 326 | 0.020 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 103 | 0.020 |
Why?
| | Immunity | 1 | 2006 | 120 | 0.020 |
Why?
| | Hyperoxia | 1 | 2006 | 97 | 0.010 |
Why?
| | Nitrites | 1 | 2005 | 74 | 0.010 |
Why?
| | Child | 2 | 2021 | 18340 | 0.010 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2006 | 102 | 0.010 |
Why?
| | RNA Interference | 1 | 2006 | 426 | 0.010 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 283 | 0.010 |
Why?
| | Caenorhabditis elegans Proteins | 1 | 2006 | 180 | 0.010 |
Why?
| | Down-Regulation | 1 | 2006 | 593 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2006 | 944 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1076 | 0.010 |
Why?
| | Survival Analysis | 1 | 2006 | 1203 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 382 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 919 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2003 | 90 | 0.010 |
Why?
| | Homeostasis | 1 | 2006 | 561 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 912 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2006 | 390 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2006 | 1643 | 0.010 |
Why?
| | Stroke Volume | 1 | 2005 | 510 | 0.010 |
Why?
| | Chimera | 1 | 2002 | 59 | 0.010 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 94 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 737 | 0.010 |
Why?
| | Neovascularization, Physiologic | 1 | 2003 | 174 | 0.010 |
Why?
| | Cell Count | 1 | 2002 | 297 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 745 | 0.010 |
Why?
| | Interleukin-1 | 2 | 1996 | 930 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2003 | 441 | 0.010 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2002 | 152 | 0.010 |
Why?
| | Bone Marrow Transplantation | 1 | 2002 | 234 | 0.010 |
Why?
| | Chemokines | 1 | 2002 | 214 | 0.010 |
Why?
| | Bleomycin | 1 | 2002 | 227 | 0.010 |
Why?
| | Hyaluronic Acid | 1 | 2002 | 189 | 0.010 |
Why?
| | Proteins | 1 | 2006 | 890 | 0.010 |
Why?
| | Chemokine CCL3 | 1 | 1999 | 15 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 1999 | 21 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1604 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 1999 | 72 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1999 | 137 | 0.010 |
Why?
| | Shivering | 1 | 1996 | 4 | 0.010 |
Why?
| | Acute-Phase Reaction | 1 | 1996 | 39 | 0.010 |
Why?
| | Lactoferrin | 1 | 1996 | 27 | 0.010 |
Why?
| | Blood Cell Count | 1 | 1996 | 50 | 0.010 |
Why?
| | Toxemia | 1 | 1996 | 5 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 154 | 0.010 |
Why?
| | Solubility | 1 | 1996 | 221 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 249 | 0.010 |
Why?
| | Kinetics | 1 | 1999 | 1528 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 5032 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 2754 | 0.010 |
Why?
| | Calmodulin | 1 | 1994 | 70 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 199 | 0.010 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 1996 | 297 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2006 | 2148 | 0.010 |
Why?
| | Electrocardiography | 1 | 1996 | 558 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1996 | 652 | 0.010 |
Why?
| | Hemodynamics | 1 | 1996 | 996 | 0.010 |
Why?
| | Cattle | 1 | 1994 | 913 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1994 | 710 | 0.010 |
Why?
| | Sulfonamides | 1 | 1994 | 442 | 0.010 |
Why?
| | Prospective Studies | 1 | 1996 | 6189 | 0.000 |
Why?
|
|
Vandivier's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|